Amylyx Pharmaceuticals (AMLX) Institutional Ownership
13F filers reported holding 90.0% of Amylyx Pharmaceuticals (AMLX) shares as of Jun 30, 2026, across 207 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 90.0%
- Jun 30, 2026
- 13F filers
- 207
- quarter ended Jun 30, 2026
- 13F value
- $2.1B
- 115.7M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | FRATES JAMES M | Chief Financial Officer | Acquired · Option exercise | 20,000 | $6.88 | ↗ |
| Nov 10, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 12,800 | $30.32 | ↗ |
| Nov 10, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 7,200 | $30.97 | ↗ |
| Nov 10, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Option exercise | 20,000Stock Option (right to buy) | — | ↗ |
| Nov 9, 2026 | FRATES JAMES M | Chief Financial Officer | Acquired · Option exercise | 20,000 | $6.88 | ↗ |
| Nov 9, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 7,700 | $29.39 | ↗ |
| Nov 9, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 12,300 | $30.11 | ↗ |
| Nov 9, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Option exercise | 20,000Stock Option (right to buy) | — | ↗ |
| Nov 9, 2026 | Klee Justin B. | Co-Chief Executive Officer | Disposed · Open-market sale | 37,483 | $29.39 | ↗ |
| Nov 9, 2026 | Klee Justin B. | Co-Chief Executive Officer | Disposed · Open-market sale | 62,517 | $30.11 | ↗ |
| Nov 9, 2026 | Cohen Joshua B | Co-Chief Executive Officer | Disposed · Open-market sale | 38,105 | $29.39 | ↗ |
| Nov 9, 2026 | Cohen Joshua B | Co-Chief Executive Officer | Disposed · Open-market sale | 61,895 | $30.11 | ↗ |
| Oct 5, 2026 | MILNE GEORGE M JR | director | Disposed · Open-market sale | 30,000 | $27.70 | ↗ |
| Sep 10, 2026 | Bedrosian Camille L | Chief Medical Officer | Disposed · Open-market sale | 7,947 | $32.21 | ↗ |
| Sep 10, 2026 | Bedrosian Camille L | Chief Medical Officer | Disposed · Open-market sale | 2,081 | $33.09 | ↗ |
| Sep 10, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 9,768 | $32.27 | ↗ |
| Sep 10, 2026 | FRATES JAMES M | Chief Financial Officer | Disposed · Open-market sale | 1,042 | $33.23 | ↗ |
| Sep 10, 2026 | Mazzariello Gina | Chief Legal Officer | Disposed · Open-market sale | 9,525 | $32.46 | ↗ |
| Sep 10, 2026 | Mazzariello Gina | Chief Legal Officer | Disposed · Open-market sale | 11 | $33.34 | ↗ |
| Sep 10, 2026 | Cohen Joshua B | Co-Chief Executive Officer | Disposed · Open-market sale | 29,545 | $32.16 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Amylyx Pharmaceuticals do institutions hold?
13F filers reported holding 90.0% of Amylyx Pharmaceuticals' shares as of Jun 30, 2026, across 207 filers.
How many 13F filers hold Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals was held by 207 13F filers as of Jun 30, 2026.
Not investment advice.

